- Trial phase
- Phase 1
- Time to market
- Unknown, at least 5-7+ years if successful. The drug is only in Phase 1 testing (safety/PK in healthy volunteers), with no Phase 2 or Phase 3 trials initiated yet.
- Why 2/10
- No hard dated binary catalyst (PDUFA, pivotal readout) is scheduled for TSP-101 in the next ~12 months. The drug is in early Phase 1 testing with no specific topline readout date announced. For argenx, TSP-101 is a very early-stage collaboration asset representing a negligible fraction of the company's value, argenx's ~$20B+ market cap is driven by its approved product Vyvgart.
TSP-101 is a very early-stage (Phase 1) asset for argenx, representing a tiny fraction of the company's value. Argenx's near-term stock movement will be driven by its approved product Vyvgart and later-stage pipeline programs (ARGX-121, ARGX-124, ARGX-213), not TSP-101. Watch for Phase 1 safety/PK data readouts from Tensegrity Pharma, but these are unlikely to move ARGX shares materially.
Price Chart
Executive Summary
TSP-101 (also known as ARGX-101) is a fully human monoclonal antibody targeting the Fn14/TWEAK receptor pathway, being developed by Tensegrity Pharma in collaboration with argenx SE (Nasdaq: ARGX). It is being investigated primarily for cancer cachexia (severe muscle wasting in cancer patients) and potentially for autoimmune diseases. The drug is in early Phase 1 clinical development, a first-in-human trial began dosing in Japan in December 2025. Argenx's involvement is through a research collaboration with an option to acquire Tensegrity Pharma. For argenx, a ~$20B+ market-cap biotech with an approved blockbuster (Vyvgart), TSP-101 is a very early-stage, low-concentration pipeline asset unlikely to drive near-term stock movement.
How It Works
TSP-101 is a monoclonal antibody (a type of lab-made immune protein) that blocks the Fn14 receptor, also known as TWEAK receptor. The TWEAK/Fn14 pathway is involved in inflammation and tissue wasting. By blocking this signal, TSP-101 aims to reduce the severe muscle wasting (cachexia) that affects many cancer patients, as well as potentially treat certain autoimmune diseases.
Trial Status
A first-in-human Phase 1 clinical trial (NCT04993768) was initiated in Japan. The first subject was dosed in December 2025. The study evaluates safety, tolerability, and pharmacokinetics of a single dose in healthy adult male volunteers. No efficacy data have been reported yet. Argenx's 2026 outlook lists TSP-101 as one of three new molecules expected to enter Phase 1 trials in 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase 1 safety and pharmacokinetics data readout (no specific date announced)
- Potential expansion of the collaboration or exercise of argenx's option to acquire Tensegrity Pharma (no timeline disclosed)
- Initiation of Phase 1/2 trials in cancer cachexia patients (timeline TBD based on Phase 1 healthy volunteer results)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ARGENX SE 6-K ARGX ·Originating report